AR and prostate cancer: 18F–Fluorodehydrotestosterone (18F–FDHT) is a less widely used testosterone analogue binding the androgen receptor, whose activation is essential for the survival and proliferation of prostate cancer cells, and the central target of medical treatment of advanced and recurrent prostate cancer.